EPKINLY Drug Scores FDA Patent Extension Lifeline
Published Date: 5/14/2025
Notice
Summary
The FDA has officially set the review period for EPKINLY, a new medicine, so its patent can be extended. This helps the company behind EPKINLY get extra time to protect their invention and encourages more innovation. If you’re involved in drug development or patents, this update affects when and how long patent protections last, potentially impacting money and market timing.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
FDA Sets Patent-Extension Period for EPKINLY
The FDA has determined the regulatory review period for EPKINLY, a human biological product, so the drugmaker can seek a patent-term extension. This lets the company get extra time to protect its invention and changes when and how long patent protections last.
May Affect Market Timing and Financial Outcomes
The notice affects drug developers and patent stakeholders by changing the timing and duration of patent protections for EPKINLY, which can influence money and market timing for related products. Those involved in drug development or patenting may see effects on revenue timing and competitive entry.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in